RxDoctor Payments Data

Robert Dambach, DO

Internal Medicine · Sugarhill, GANPI 1538161252

Payments from drug & device makers

$558in general payments, 2019–2025

Across 8 payments — averaging $69.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$210
  • Welch Allyn$210
  • Exact Sciences$60
  • Boston Scientific$40
  • GSK$20
  • Pfizer$17

What the payments were for

  • Food & beverage$13725%
  • Other$42175%

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Baxter Healthcare1$210
Welch Allyn1$210
Exact Sciences3$60
Boston Scientific1$40
GSK1$20
Pfizer1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$558 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$168,207
Medicare patients
556
Services billed
6,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$114,630
OzempicSemaglutide64$104,765
EliquisApixaban85$90,987
JanuviaSitagliptin Phosphate31$31,182
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$25,375
LinzessLinaclotide26$24,308
FarxigaDapagliflozin Propanediol15$21,119
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$18,255
MyrbetriqMirabegron12$11,054
Lamictal XrLamotrigine14$10,528
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$6,588
Insulin Lispro Kwikpen U-100Insulin Lispro16$4,721
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,529
Novolog FlexpenInsulin Aspart14$3,071
SynthroidLevothyroxine Sodium26$2,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$90,98785 claims
GSKTrelegy Ellipta, Shingrix$20$29,90450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Sugarhill

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →